Annals of internal medicine
-
Randomized Controlled Trial Multicenter Study
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent. ⋯ Adalimumab induces remissions more frequently than placebo in adult patients with Crohn disease who cannot tolerate infliximab or have symptoms despite receiving infliximab therapy. For more information on adalimumab in Crohn disease, click here. ClinicalTrials.gov registration number: NCT00105300.
-
Randomized Controlled Trial Multicenter Study
Physiotherapist-directed exercise, advice, or both for subacute low back pain: a randomized trial.
Advice and exercise are widely recommended for subacute low back pain, but the effectiveness of these interventions is unclear. ⋯ In participants with subacute low back pain, physiotherapist-directed exercise and advice were each slightly more effective than placebo at 6 weeks. The effect was greatest when the interventions were combined. At 12 months, the only effect that persisted was a small effect on participant-reported function. AUSTRALIAN CLINICAL TRIALS REGISTRY REGISTRATION NUMBER: 12605000039684.